Tumor Necrosis Factor-α Blockers in SAPHO Syndrome: Table 1.

Abdelghani, K. Ben; Dran, Delphine Gerard; Gottenberg, Jacques-Éric; Morel, Jacques; Sibilia, Jean; Combe, Bernard

doi:10.3899/jrheum.091086

Cited by 96 publications

(63 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adalimumab is a humanized monoclonal TNF antibody that is administered subcutaneously and is approved for the use in children and adolescents with JIA [26,31]. It has been successfully used to treat refractory SAPHO syndrome [3], and in our patient, symptoms resolved completely after adalimumab was given. Nevertheless, an increased risk of opportunistic infections, especially tuberculosis, must be kept in mind when using TNF blockers on a wider scale.…”

Section: Discussionmentioning

confidence: 91%

Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent

et al. 2011

View full text Add to dashboard Cite

Life-threatening disseminated tuberculosis developed in a 17-year-old girl who was treated with the TNF-α blocker adalimumab for refractory SAPHO syndrome. The patient presented to the emergency department with dyspnea and somnolence and within 2 h developed the clinical picture of a septic shock. In addition to this unusual presentation, she showed a complicated course with increasing cerebral granuloma formation in spite of adequate antimycobacterial treatment. Immune reconstitution after discontinuation of TNF blockade may contribute to this "paradoxical reaction." Possible implications for screening, diagnosis, and treatment of tuberculosis in children and adolescents receiving anti-TNF treatment are discussed.

show abstract

Section: Discussionmentioning

confidence: 91%

Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent

et al. 2011

View full text Add to dashboard Cite

show abstract

“…132,133 TNF-alfa blockade with infliximab, etanercept, or adalimumab can be helpful for some patients. 134 Several case reports have documented response of skin manifestations to colchicine (1-1.5 mg/d), prednisone (5 mg/d), etretinate (20-50 mg/d), dapsone, and tonsillectomy. [134][135][136][137][138][139][140][141][142] …”

Section: Hyper-igd Syndromementioning

confidence: 98%

Autoinflammation: From monogenic syndromes to common skin diseases

Nguyen

Cowen

Leslie

2013

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Autoinflammation is characterized by aberrant regulation of the innate immune system and often manifests as periodic fevers and systemic inflammation involving multiple organs, including the skin. Mutations leading to abnormal behavior or activity of the interleukin 1 beta (IL-1ß)-processing inflammasome complex have been found in several rare autoinflammatory syndromes, for which anticytokine therapy such as IL-1 or tumor necrosis factor-alfa inhibition may be effective. It is becoming clear that features of autoinflammation also affect common dermatoses, some of which were previously thought to be solely autoimmune in origin (eg, vitiligo, systemic lupus erythematosus). Recognizing the pathogenetic role of autoinflammation can open up new avenues for the targeted treatment of complex, inflammatory dermatoses.

show abstract

“…Abdelghani BK et al [122] 6 SAPHO Adalimumab -1 patient (40mg every 2 weeks) 4 patients with clinical improvement (1 patient had a psoriatic rash while on infliximab with response to etanercept) Etanercept -1 patient 1 patient with transient improvement with infliximab, who, due to an allergic urticarial reaction, was switched to adalimumab and had a partial response Infliximab -4 patients (5 mg/kg at Weeks 0, 2, and 6 and every 8 weeks thereafter)…”

Section: Clinical Improvementmentioning

confidence: 99%

Chronic Recurrent Multifocal Osteomyelitis

Costa-Reis

Sullivan

2013

J Clin Immunol

View full text Add to dashboard Cite

Chronic recurrent multifocal osteomyelitis is a rare auto-inflammatory condition that primarily affects children and adolescents. It presents with recurrent episodes of pain related to the presence of foci of sterile bone inflammation. The long bones of the lower extremities are more frequently affected and the spine can also be involved. Imaging studies, including whole-body magnetic resonance, are important for diagnosis and detection of asymptomatic lesions. Bone biopsies may be necessary to exclude other diseases, including malignancy and infections. Non-steroidal anti-inflammatory drugs cause relief of symptoms in the majority of cases. Bisphosphonates and TNF-α blockers are alternatives for patients who do not respond or who have spinal involvement.

show abstract

Tumor Necrosis Factor-α Blockers in SAPHO Syndrome: Table 1.

Abstract: Given our results and those from the literature, TNF-alpha blockers should be considered in the therapeutic strategy of refractory cases of SAPHO syndrome, despite their effect seeming less impressive than in other spondyloarthropathies.

Cited by 96 publications

References 16 publications

Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent

Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent

Autoinflammation: From monogenic syndromes to common skin diseases

Chronic Recurrent Multifocal Osteomyelitis

Contact Info

Product

Resources

About